Dermira Investor Presentation — May 2018

Document content

DERMIRA | ANALYST & INVESTOR DAY –MAY 24, 2018

Skin Science Re- envisioned, Re- examined, and Re- imaginedAnalyst & Investor Day

May 24, 20182 DERMIRA | ANALYST & INVESTOR DAY –MAY 24, 2018

Ian Clements, Ph.D., Vice President, Investor Relations3 DERMIRA | ANALYST & INVESTOR DAY –MAY 24, 2018Forward- Looking Statements

This presentation contains forward- looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

Exchange Act of 1934, as amended, which are subject to the “ safe harbor ” created by those sections, including statements and information with respect to: market size for hyperhidrosis and

atopic dermatitis and our potential market opportunities; the expected date by which the Food and Drug Administration (FDA) w illcomplete its substantive review of our New Drug Application

(NDA) for glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis and potential approval thereof; the growth of our commercial organization and our plans for the commercial

launch of glycopyrronium tosylate if regulatory approval is obtained; anticipated levels of insurance coverage for glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis; our

business strategy, objectives and opportunities; the completion of, and timing expectations for the receipt and announcement of topline results from, our Phase 2b dose- ranging study of

lebrikizumab for moderate- to-severe atopic dermatitis; our future business and product development, clinical and regulatory plans; our product goals, attributes and performance; and our 2018

financial guidance, including estimates of revenue, operating expense, stock -based compensation expense, the split between research and development costs and sales, general and

administrative costs and the timing for such expenses, cash runway and anticipated payments to Roche. Forward- looking statements are subject to known and unknown risks, uncertainties,

assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward- looking

statements, including, but not limited to, risks relating to the design, implementation and outcome of our clinical trials, i ncluding related to further analysis of the results of our studies; our

dependence on third- party clinical research organizations, manufacturers and suppliers; the outcomes of our future meetings with regulatory agencies; our ability to attract and retain key

employees; our ability to obtain necessary additional capital; market acceptance of our potential products; our ability to devel op and maintain collaborations and license products and intellectual